Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Argos HIV Immunotherapy Offers Potential Reprieve From Antiretrovirals

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

HIV patients armed with a new immunotherapy targeted at their personal viral load may be able to take a break from the oppression of antiretroviral therapy or even drop it altogether, if Argos Therapeutics' AGS-004 continues to meet with clinical success

You may also be interested in...



It's A Start: Experimental HIV Vaccine Regimen Cuts Disease Risk By A Third In Thai Volunteers

Six-year U.S. Army/NIH-sponsored study conducted in 16,000-plus Thai adults shows 31.2% decreased risk of infection, but better efficacy is needed.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals

Product

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel